Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208399 | 0.87 | ADORA2A (0.50) | NOS1 | |
| SCHEMBL26500537 | 0.86 | NOS1 (0.62) | NOS1DHFR | |
| SCHEMBL12844585 | 0.84 | NOS1 (0.46) | NOS1 | |
| SCHEMBL14435374 | 0.84 | NOS1 (0.55) | NOS1DHFR | |
| SCHEMBL30432658 | 0.84 | NOS1 (0.55) | NOS1DHFR | |
| SCHEMBL20780857 | 0.83 | NOS1 (0.67) | NOS1DHFR | |
| SCHEMBL10850465 | 0.83 | NOS1 (0.71) | NOS1DHFR | |
| SCHEMBL15075219 | 0.83 | NOS1 (0.45) | NOS1DHFR | |
| SCHEMBL10615664 | 0.83 | NOS1 (0.62) | NOS1DHFR | |
| SCHEMBL10852865 | 0.82 | NOS1 (0.82) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MICROMASS UK LIMITED (GB) | 2021-01-05 | — | — | US | disclosed |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MICROMASS UK LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
| EP-2797417-B1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | HEINRICH HEINE UNIVERSITAT DUSSELDORF (DE) | 2015-08-06 | — | — | US | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | TYDOCK PHARMA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH INC. | 2010-01-07 | — | — | US | disclosed |
| US-20080207652-A1 | Novel inhibitors of folic acid-dependent enzymes | STOICESCU DAN | 2008-08-28 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| WO-1997021711-A1 | PROCESS FOR PREPARING 4-AMINOPTERIDINE DERIVATIVES | LONZA AG (CH) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MTX1, MTX2, MTHFD2 | NOS1 4211/4885DHFR 4/4885 |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | NOS1 3043/4885DHFR 1022/4885 |
| US-20100305134-A1 | SPECIFIC INHIBITORS OF PTERIDINE REDUCTASE WITH ANTIPARASITIC ACTION | QDPR, DHFR, DDC | NOS1 1167/4885DHFR 2/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | NOS1 3800/4885DHFR 405/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | NOS1 3584/4885DHFR 487/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | NOS1 4318/4885DHFR 2599/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | NOS1 1249/4885DHFR 1951/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | NOS1 1249/4885DHFR 1951/4885 |
| US-20080207652-A1 | Novel inhibitors of folic acid-dependent enzymes | FOLR2, FOLR1, DHFR | NOS1 1451/4885DHFR 3/4885 |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | CBR3, GRHPR, PCK1 | NOS1 4480/4885DHFR 703/4885 |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MTX1, MTX2, MTHFD1 | NOS1 2690/4885DHFR 8/4885 |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | DHFR, MTHFD1, OAT | NOS1 2505/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.